Quest Diagnostics Incorporated with ticker code (DGX) now have 14 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 185 and 129 calculating the average target price we see 151.71. Given that the stocks previous close was at 137.19 this indicates there is a potential upside of 10.6%. The 50 day moving average now sits at 136.72 and the 200 day moving average is 145.64. The company has a market cap of $15,985m. Visit the company website at: https://www.questdiagnostics.com
The potential market cap would be $17,676m based on the market concensus.
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
